Le Lézard
Classified in: Health
Subject: SVY

Respiratory Tract Infections Drug Development Pipeline Review 2018 Featuring Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline


DUBLIN, Aug. 17, 2018 /PRNewswire/ --

The "Respiratory Tract Infections Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Respiratory Tract Infections Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.

Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.

Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.

Scope

Reasons to buy

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/cx9h52/respiratory_tract?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: